Clinical Trials
36 trialsFiREBOLT
Eli Lilly and Company
OMNIRAY
Eli Lilly and Company
NEXUS-01
Eli Lilly and Company
A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
Immunome, Inc.
PIONEER
University of Utah
18F-AraG PET/CT as a Non-Invasive Imaging Biomarker for Chemoradiation Treatment Response in Esophageal Cancer
M.D. Anderson Cancer Center
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
AbbVie
Brodalumab in the Treatment of Immune-Related Adverse Events
Columbia University
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Seagen Inc.
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer
Washington University School of Medicine
Phase 1 Study of PF-08046033 in Advanced Solid Tumors
Pfizer
A Study Evaluating the Safety and Efficacy of AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1)
Aurigene Discovery Technologies Limited
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Pfizer
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
SystImmune Inc.
CHANCES
Institut Paoli-Calmettes
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
Sutro Biopharma, Inc.
IDOV-Immune for Advanced Solid Tumors
ViroMissile, Inc.
VISTA
Baylor College of Medicine
A Study of SH009 Injection in Patients With Advanced Solid Tumors.
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
SystImmune Inc.
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
Phrontline Biopharma
Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy
Henry Ford Health System
CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors
Chongqing Precision Biotech Co., Ltd
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd.
A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
Jonsson Comprehensive Cancer Center
A Multi Tumor, Open Phase I Clinical Study on the Progression of First-line Anti-tumor Therapy Using Cardonizumab Combined With Pulsed Low-dose Rate External Irradiation (PLDR)
Anhui Provincial Hospital
Phase I Study of BC008-1A Injection in Patients With Advanced Solid Tumors
Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.
APG-2449 in Patients With Advanced Solid Tumors
Ascentage Pharma Group Inc.
RIOT3
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
AB122 Platform Study
Taiho Pharmaceutical Co., Ltd.
MYE Symphony
Myeloid Therapeutics
Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes(CAR-T) for CEA Positive Advanced Malignant Solid Tumors
Chongqing Precision Biotech Co., Ltd
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
Chongqing Precision Biotech Co., Ltd
A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors
Chongqing Precision Biotech Co., Ltd